Immunovant/$IMVT
13:30
03:10
16:45
06:25
20:00
1D1W1MYTD1Y5YMAX
About Immunovant
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
Ticker
$IMVT
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
362
ISIN
US45258J1025
Website
Immunovant Metrics
BasicAdvanced
$2.7B
-
-$2.73
0.61
-
Price and volume
Market cap
$2.7B
Beta
0.61
52-week high
$32.95
52-week low
$12.72
Average daily volume
1.3M
Financial strength
Current ratio
11.162
Quick ratio
10.418
Total debt to equity
0.014
Profitability
EBITDA (TTM)
-437.775
Effective tax rate (TTM)
-0.22%
Management effectiveness
Return on assets (TTM)
-37.97%
Return on equity (TTM)
-62.46%
Valuation
Price to book
3.81
Price to tangible book (TTM)
3.81
Price to free cash flow (TTM)
-6.383
Free cash flow yield (TTM)
-15.67%
Free cash flow per share (TTM)
-248.48%
Growth
Earnings per share change (TTM)
45.39%
3-year earnings per share growth (CAGR)
24.09%
What the Analysts think about Immunovant
Analyst ratings (Buy, Hold, Sell) for Immunovant stock.
Bulls say / Bears say
Citi initiated coverage on Immunovant with a 'buy' rating, citing excitement about the company's pipeline of assets to treat autoimmune diseases, including lead candidate batoclimab and potential applications for IMVT-1402. (seekingalpha.com)
Immunovant announced a $450 million private placement in January 2025, with participation from a U.S.-based healthcare-focused investor, a large mutual fund complex, and Roivant, bringing Roivant’s basic ownership up to approximately 57%. (fox59.com)
Piper Sandler analyst Yasmeen Rahimi maintained a 'Buy' rating on Immunovant with a price target of $57.00, indicating strong confidence in the company's future performance. (markets.businessinsider.com)
Immunovant reported a net loss of $307.4 million ($2.10 per common share) for the nine months ended December 31, 2024, compared to $184.0 million ($1.36 per common share) for the same period in 2023, indicating increasing financial losses. (globenewswire.com)
Research and development expenses increased to $75.5 million for the three months ended June 30, 2024, up from $50.6 million for the same period in 2023, reflecting higher costs associated with clinical trials and personnel. (markets.businessinsider.com)
General and administrative expenses rose to $57.1 million for the nine months ended December 31, 2024, compared to $42.5 million for the same period in 2023, primarily due to higher personnel-related expenses and other costs. (globenewswire.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
Immunovant Financial Performance
Revenues and expenses
Immunovant Earnings Performance
Company profitability
Immunovant News
AllArticlesVideos
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025
GlobeNewsWire·3 weeks ago
IMVT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for Immunovant stock?
Immunovant (IMVT) has a market cap of $2.7B as of June 20, 2025.
What is the P/E ratio for Immunovant stock?
The price to earnings (P/E) ratio for Immunovant (IMVT) stock is 0 as of June 20, 2025.
Does Immunovant stock pay dividends?
No, Immunovant (IMVT) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Immunovant dividend payment date?
Immunovant (IMVT) stock does not pay dividends to its shareholders.
What is the beta indicator for Immunovant?
Immunovant (IMVT) has a beta rating of 0.61. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
